Kane Biotech Inc. · TSXV:KNE
Kane Biotech — Investor Presentation (May 2026)
14 slides from Kane Biotech's investor presentation, May 2026
Slide 1: Disrupting Biofilms to Save Limbs and Transform Wound Care
I n t r o d uct i o n P r esen t a t i o n | M a y 2 0 2 6 Disrupting Biofilms to Save Limbs and Transform Wound Care "Every 4 minutes, a diabetic patient in America loses a limb." Dr. Robert Huizinga rhuizinga@kanebiotech.com Interim Chief Executive Officer www.kanebiotech.com TSX-V:KNE OTC:KNBIF
Slide 2: Forward-Looking Statements
LEGAL DISCLAIMER Forward-Looking Statements This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cau
Slide 3: A Preventable Healthcare Crisis in the US ($USD)
THE PROBLEM A Preventable Healthcare Crisis in the US ($USD) The human and economic burden of chronic wounds is escalating 130,000 10.5M 700,000 >$100K USD Amputations per year among Medicare beneficiaries suffering Burn-related insurance claims diabetic patients from chronic wounds annually Average
Slide 4: A Preventable Healthcare Crisis in Canada ($CAD)
THE PROBLEM A Preventable Healthcare Crisis in Canada ($CAD) * Excludes outpatient care, rehabilitation, prosthetics, and long-term support. $47,000 $750M >$12 Billion 3-5 Times Average cost per hospitalization for Annual hospitalization costs for Estimated annual direct spending on First Nations pe
Slide 5: Biofilms: The 1,000X Problem
THE SCIENCE Biofilms: The 1,000X Problem Why standard treatments fail to heal chronic wounds The Hidden Culprit What Is A Biofilm? A protective microscopic matrix created by bacteria to defend themselves 70% of burn wounds contain biofilm layers Reduces metabolic activity (making bacteria "invisible
Slide 6: Why Current Solutions Fail
COMPETITIVE LANDSCAPE Why Current Solutions Fail Existing standards of care leave critical gaps in treatment: revyve® has the potential to be the standard of care. Surgical Debridement Current Advanced Antibiotic Hydrogels Dressings Treatments Painful and traumatic procedure No biofilm disruption ca
Slide 7: $423M - $493M US Market Opportunity
THE OPPORTUNITY $423M - $493M US Market Opportunity TOTAL TAM: $400M - $500M Addressing massive unmet needs across multiple care settings $350M $80-150M Chronic Wounds Inpatient Burn/Wound Diabetic Foot Ulcers (DFUs) 450,000 Burn Patients/Year Venous/Arterial Leg Ulcers Large Surface Area Wounds Pre
Slide 8: revyve®: Three Mechanisms in One
THE SOLUTION revyve®: Three Mechanisms in One The first technology to disrupt biofilms, kill bacteria, and support healing Biofilm Disruption Antimicrobial Killing Healing Support Patented coactiv+ technology breaks down the Sustained killing of bacteria for up to 7 days Thermo-reversible gel suppor
Slide 9: 7-Day Biofilm Killing Power
CLINICAL DATA 7-Day Biofilm Killing Power Sustained activity against antibiotic-resistant pathogens without regrowth >4 Log Reduction (99.99%+ Kill Rate) Sustained 7-Day Activity (No Regrowth) Effective vs. Antibiotic-Resistant Strains (MRSA) Mature 72h Biofilm Model Escherichia coli Gram-Negative S
Slide 10: Real World Case Series – Multiple Centers
REAL WORLD VALIDATION Real World Case Series – Multiple Centers Consistent outcomes across 9 leading wound care centers in the US and Canada Case Series Design 9 ~45 2 Centers Patients Countries Q4 2025 – PRELIMINARY FINDINGS Q1 2026 High rate of conversion from non-healing to healing transition Out
Slide 11: From Non-Healing to Healed
CLINICAL PROOF From Non-Healing to Healed Disrupting biofilms changes outcomes for chronic wound patients Case Study 1: 52-Year-Old Male with Diabetic Foot Ulcer Quinte Health Care History: Multiple unsuccessful treatments prior to revyve® Day 1 Day 97 After Study End FULLY HEALED Baseline Near clos
Slide 12: Product Portfolio
PRODUCT PORTFOLIO Product Portfolio Two FDA-cleared formats covering the full spectrum of wound care needs Antimicrobial Wound Gel Antimicrobial Wound Spray Tube Format (85g/3 oz) Non-Aerosol Spray (5 oz) Thermo-reversible: Liquid at cool temp, gel at body temp Zero-Contact: Painless application for
Slide 13: Transforming Wound Care
INVESTMENT SUMMARY Transforming Wound Care Preventing amputations. Creating shareholder value. The Problem The Solution The Market The Inflection The Investment 130,000 revyve® $423M+ USD NOW VALUE AMPUTATIONS / YEAR DISRUPTS & KILLS US ADDRESSABLE MARKET EXECUTION PHASE ASYMMETRIC UPSIDE Biofilms b
Slide 14: Partner With Us to Transform Wound Care
LET'S CONNECT Partner With Us to Transform Wound Care Join us in preventing amputations and creating shareholder value Dr. Robert Huizinga, PhD, RN Interim Chief Executive Officer rhuizinga@kanebiotech.com www.kanebiotech.com Ray Dupuis, CPA, MBA Chief Financial Officer rdupuis@kanebiotech.com ir@ka